Search Within

Kristine Peregrino Lacuna

Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Department of Medicine (5)
  2. Genitourinary Oncology Service (5)
  3. Solid Tumor Oncology Division (5)
  4. Biostatistics Service (2)
  5. Epidemiology and Biostatistics (2)
  6. GSK Faculty (1)

More Groups

People
  1. Howard Scher (4)
  2. Michael Morris (4)
  3. Charles Ryan (2)
  4. Glenn Heller (2)
  5. Aliaksandra Samoila (1)
  6. Aseem Anand (1)

More People

Years
  1. 2025 (2)
  2. 2021 (1)
  3. 2014 (1)
  4. 2013 (2)
Publications
  1. Journal of Clinical Oncology (4)
  2. European Journal of Nuclear Medicine and Molecular Imaging (1)
  3. European Urology Oncology (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier BV (1)
  3. Springer (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers
    Meeting Abstract

    Lacuna, K. P.; Ishani, K.; Boytim, E.; Abida, W.; Morris, M. J.; Antonarakis, E. S.; Hwang, J.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Ryan, C. J.; Lacuna, K. P.; Yoo, L.; Szmukier, Z.; Boldt-Houle, D. M.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503)
    Journal Article

    Morris, M. J.; Mota, J. M.; Lacuna, K.; Hilden, P.; Gleave, M.; Carducci, M. A.; Saad, F.; Cohn, E. D.; Filipenko, J.; Heller, G.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), +/- docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results
    Meeting Abstract

    Morris, M. J.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Lacuna, K. P.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Heller, G.; Danila, D. C.; Anand, A.; Lacuna, K. P.; Samoila, A.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
    Journal Article

    Carrasquillo, J. A.; O'Donoghue, J. A.; Pandit-Taskar, N.; Humm, J. L.; Rathkopf, D. E.; Slovin, S. F.; Williamson, M. J.; Lacuna, K.; Aksnes, A. K.; Larson, S. M.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2013)

    Fulltext@MSK | Save